Transgenic technology: the strategy for the control and prevention of bovine staphylococcal mastitis?

Cardoso, Clarissa Varajão; Barbosa, Eunice Ventura; Liberal, Maíra Halfen Teixeira; Chagas, Evelize Folly das

doi:10.1016/j.biori.2019.08.001

Cited by 6 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5. Using modern technology such as genetic engineering and biotechnology (Cardoso et al, 2019), genomic selection (Kaniyamattam et al, 2020), and nanoemulsion formula (Machado et al, 2020), etc.…”

Section: Discussionmentioning

confidence: 99%

Presence of Antibiotic-Resistant in Staphylococcal Subclinical Mastitis in Several Regencies of East Java, Indonesia

Widianingrum¹,

Khasanah

Addy

2022

Trop. Anim. Sci. J.

View full text Add to dashboard Cite

Staphylococcal mastitis has been reported as a serious dairy disease in various regions around the world. The occurrence of resistant strains in Staphylococcus species to antibiotics has triggered alternative treatment substituting antibiotic usage on the global scene. This study aimed to investigate the presence of antibiotic-resistant genes in Staphylococcal subclinical-mastitis cases present in several regencies of East Java Province, Indonesia. A total of 592 quarter milk samples were collected from 62 farms in the region with high dairy cattle populations in Lumajang,

show abstract

Section: Discussionmentioning

confidence: 99%

Presence of Antibiotic-Resistant in Staphylococcal Subclinical Mastitis in Several Regencies of East Java, Indonesia

Widianingrum¹,

Khasanah

Addy

2022

Trop. Anim. Sci. J.

View full text Add to dashboard Cite

show abstract

“…To address the issues of disease relapse, lysostaphin-secreting transgenic cows were developed. These transgenic cows secrete lysostaphin in their milk at concentrations ranging from 0Á9 to 14 mg ml À1 and was protected from bovine mastitis (Cardoso et al 2019).…”

Section: Anti-staphylococcal Activity Of Lysostaphin As Single Drug Moleculementioning

confidence: 99%

Therapeutic applications of lysostaphin against Staphylococcus aureus

Jayakumar

Kumar

Biswas

et al. 2021

J of Applied Microbiology

View full text Add to dashboard Cite

Staphylococcus aureus, an opportunistic pathogen, causes diverse community and nosocomial-acquired human infections, including folliculitis, impetigo, sepsis, septic arthritis, endocarditis, osteomyelitis, implant-associated biofilm infections and contagious mastitis in cattle. In recent days, both methicillinsensitive and methicillin-resistant S. aureus infections have increased. Highly effective anti-staphylococcal agents are urgently required. Lysostaphin is a 27 kDa zinc metallo antimicrobial lytic enzyme that is produced by Staphylococcus simulans biovar staphylolyticus and was first discovered in the 1960s. Lysostaphin is highly active against S. aureus strains irrespective of their drug-resistant patterns with a minimum inhibitory concentration of ranges between 0Á001 and 0Á064 lg ml À1 . Lysostaphin has activity against both dividing and non-dividing S. aureus cells; and can seep through the extracellular matrix to kill the biofilm embedded S. aureus. In spite of having excellent anti-staphylococcal activity, its clinical application is hindered because of its immunogenicity and reduced bio-availability. Extensive research with lysostaphin lead to the development of several engineered lysostaphin derivatives with reduced immunogenicity and increased serum half-life. Therapeutic efficacy of both native and engineered lysostaphin derivatives was studied by several research groups. This review provides an overview of the therapeutic applications of native and engineered lysostaphin derivatives developed to eradicate S. aureus infections.

show abstract

“…At least one intra-mammary injection of 100 mg rLYS95 in 60 ml phosphate buffered saline (PBS) cures 95% of udder infection with Staphylococcus aureus. The antibacterial activity of rLYS in vitro persisted for 72 hours, but in vivo most of the infected mammary glands remained in the body for 72 hours after treatment [59].…”

Section: Lysostaphin As An Anti-staphylococcal Therapeutic Agentmentioning

confidence: 99%

Staphylococcus aureus and Dairy Udder

Aqib¹,

Ijaz²,

Shoaib³

et al. 2021

Insights Into Drug Resistance in Staphylococcus Aureus

View full text Add to dashboard Cite

Staphylococcus aureus is a major causative agent of intra-mammary infections in dairy animals with potential virulence of surface components, toxins, and extracellular enzymes. About 74% quarter prevalence of S. aureus in bovine udder with overall prevalence exceeding 61% in dairy animals. About 17 different serotypes of dairy originated S. aureus have been reported with 24 virulence coding genes for leukocidins (lukED/lukM), pyrogenic toxin super antigen (PTSAg), haemolysins (hla-hlg), toxic-shock syndrome toxin (tst), enterotoxins (sea-seo, seu), exfoliative toxins (eta, etb), and genes for methicillin (mecA) and penicillin (blaZ) resistance. Attainment of refuge inside the macrophages and neutrophils is a major cause of S. aureus mastitis persistence. Mammary prebiotics and probiotics are recently being used as alternatives to antibiotic for the prevention of mastitis. Literature showed anti- staphylococcus vaccines with different results depending upon types of immunization, route of administration and adjuvant used. Studies has shown that herd specific as well as commercial S. aureus vaccines reduce new infections in dairy animals. Experiments are still in progress for the use of vaccines against S. aureus mastitis with optimal efficacy and reliability. Perhaps, there might be bright future because of highly satisfactory trial results of mastitis vaccines in the lab animals.

show abstract

Transgenic technology: the strategy for the control and prevention of bovine staphylococcal mastitis?

Cited by 6 publications

References 44 publications

Presence of Antibiotic-Resistant in Staphylococcal Subclinical Mastitis in Several Regencies of East Java, Indonesia

Presence of Antibiotic-Resistant in Staphylococcal Subclinical Mastitis in Several Regencies of East Java, Indonesia

Therapeutic applications of lysostaphin against Staphylococcus aureus

Staphylococcus aureus and Dairy Udder

Contact Info

Product

Resources

About